Cargando…
Baracle(®) vs Baraclude(®) for 48 weeks in patients with treatment-naïve chronic hepatitis B: a comparison of efficacy and safety
BACKGROUND AND OBJECTIVE: Entecavir (ETV) is a standard of care for chronic hepatitis B (CHB). In a bioequivalence study, ETV from Dong-A ST (Baracle(®)) was found to have a pharmacokinetic profile equivalent to ETV from Bristol-Myers Squibb (BMS) (Baraclude(®)). The present study was conducted to e...
Autores principales: | Kim, Do Young, Kim, Ju Hyun, Tak, Won Young, Yeon, Jong Eun, Lee, Joon Hyeok, Yoon, Jung Hwan, Lee, Youn Jae, Lee, Byung Seok, Han, Byung Hoon, Lee, Han Chu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5673034/ https://www.ncbi.nlm.nih.gov/pubmed/29184389 http://dx.doi.org/10.2147/DDDT.S149199 |
Ejemplares similares
-
Treatment Outcomes of Clevudine versus Lamivudine at Week 48 in Naïve Patients with HBeAg Positive Chronic Hepatitis B
por: Kim, In Hee, et al.
Publicado: (2010) -
Phase II study of weekly paclitaxel and capecitabine in patients with metastatic or recurrent esophageal squamous cell carcinoma
por: Yun, Tak, et al.
Publicado: (2011) -
Efficacy of Initial Treatment with Clevudine in Naive Patients with Chronic Hepatitis B
por: Yang, Hyeon Woong, et al.
Publicado: (2010) -
Clinical impact of the early alanine amininotransferase flare during tenofovir monotherapy in treatment-naïve patients with chronic hepatitis B
por: Seo, Hee Yeon, et al.
Publicado: (2017) -
A Phase II Study of Weekly Paclitaxel Plus Gemcitabine as a Second-Line Therapy in Patients with Metastatic or Recurrent Small Cell Lung Cancer
por: Yun, Tak, et al.
Publicado: (2016)